Skip to main content

TGV Therapeutics working with NIH on novel anti-fungal against deadly C.auris

News Source: WiredPRNews.com
New York, NY, USA, 02/15/2018 /SubmitPressRelease123/


TGV Therapeutics, the pharmaceutical company developing first-in-class drugs for fighting antibiotic-resistant infections, announced today it is working with the National Institutes of Health to expand its research on a drug that shows promise against new fungal superbugs.



TGV Therapeutics and its advisors, Dr.

News Source: http://www.WiredPRNews.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.